Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term PROGNOSTIC-SIGNIFICANCE. Found 8 abstracts

Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX. Risk Factors for GI Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2014 Apr;32(12):1210-7.   PMCID: PMC3986384
Guo YP, Kock K, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M. Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival. Clinical Cancer Research. 2009 Mar;15(5):1762-9.
Darcy KM, Brady WE, McBroom JW, Bell JG, Young RC, McGuire WP, Linnolia RI, Hendricks D, Bonome T, Farley JH. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group study. Gynecologic Oncology. 2008 Dec;111(3):487-95.
Kulkarni S, Patil DB, Diaz LK, Wiley EL, Morrow M, Khan SA. COX-2 and PPAR gamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC cancer. 2008 Jan;8:36.
Pro B, Leber B, Smith M, Fayad L, Romaguera J, Hagemeister F, Rodriguez A, McLaughlin P, Samaniego F, Zwiebel J, Lopez A, Kwak L, Younes A. Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. British Journal of Haematology. 2008 Nov;143(3):355-60.
D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1082-7.
Travis WD, Garg K, Franklin WA, Wistuba, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: The clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. Journal of Thoracic Oncology. 2006 Nov;1(9):S13-S19.
Arias-Mendoza F, Smith MR, Brown TR. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Academic radiology. 2004 Apr;11(4):368-76.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term PROGNOSTIC-SIGNIFICANCE

PROGNOSTIC-SIGNIFICANCE EXPRESSION SURVIVAL CARCINOMA RECEPTOR BOWEL FEATURES GEFITINIB rituximab REGRESSION TUMOR ANGIOGENESIS APOPTOSIS GROUND-GLASS OPACITY MAGNETIC-RESONANCE SPECTROSCOPY HUMAN BREAST-CANCER CISPLATIN-BASED CHEMOTHERAPY non-Hodgkin's lymphoma GROWTH ARREST LUNG-CANCER ACUTE LYMPHOBLASTIC-LEUKEMIA non-Hodgkin lymphoma pathology THERAPY in vivo metabolism SPECIMENS CERVICAL-CANCER MYELODYSPLASTIC OVER-EXPRESSION GENE-EXPRESSION lung cancer THIN-SECTION CT HIGH-RESOLUTION CT PACLITAXEL resistance classification CELL oblimersen sodium Prognostic markers prostate ANTI-CD20 MONOCLONAL-ANTIBODY CYCLOPHOSPHAMIDE Oncology IHC Gleason score adenocarcinoma PERFORATION MORPHOLOGIC METABOLIC CHARACTERIZATION GASTROINTESTINAL PERFORATION CYCLIC-NUCLEOTIDES radiology LIGAND TROGLITAZONE p53 GENE CHRONIC LYMPHOCYTIC-LEUKEMIA EFFICACY SCINTIGRAPHY RADICAL PROSTATECTOMY bronchioloalveolar carcinoma PROTEIN GLEASON GRADE TISSUE MICROARRAYS CYCLOOXYGENASE-2 CANCER ANGIOGENESIS INHIBITOR PLATINUM-BASED CHEMOTHERAPY FACTOR HUMAN Ovarian cancer treatment predictor RADIATION-THERAPY RECURRENT EPITHELIAL OVARIAN ANTIGEN MEN GENE-MUTATIONS IN-VIVO C-MYC phospholipid intermediates ACTIVATED RECEPTOR-GAMMA HUMAN BRAIN KeyWords Plus: MULTIDRUG-RESISTANCE PROTEIN-4 P-31 MR spectroscopy ADENOCARCINOMA CANCER-CELLS drug sensitivity TRANSPORTER SUPERFAMILY CROHNS-DISEASE CYCLIN D1 PERIPHERAL PSA ERA ENDOTHELIAL GROWTH-FACTOR B-CELL LYMPHOMA LOCAL RECURRENCE COMPUTED-TOMOGRAPHY SYNDROME P-GLYCOPROTEIN recurrent B-cell NHL Gleason pattern POOR-PROGNOSIS radiation therapy Overexpression PROTEIN EXPRESSION
Last updated on Friday, June 05, 2020